These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 8656556

  • 1. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S, Akakura K, Shimazaki J.
    Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
    Akimoto S, Inomiya H, Furuya Y, Akakura K, Ito H.
    Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
    [Abstract] [Full Text] [Related]

  • 7. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma.
    Hosoya Y, Arai K, Honda M, Sumi S, Yoshida K.
    Eur Urol; 1997 Aug; 31(2):220-3. PubMed ID: 9076470
    [Abstract] [Full Text] [Related]

  • 8. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y, Ochi M, Tokue A.
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
    Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, Honda M, Yano M, Moriguchi H, Kitahara S.
    Cancer; 1997 Nov 01; 80(9):1760-7. PubMed ID: 9351545
    [Abstract] [Full Text] [Related]

  • 12. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
    Fukumitsu N, Uchiyama M, Mori Y, Kishimoto K, Nakada J.
    Ann Nucl Med; 2003 Jun 01; 17(4):297-303. PubMed ID: 12932112
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
    Kobayashi Y, Tokue A.
    Nihon Rinsho; 1998 Aug 01; 56(8):2072-6. PubMed ID: 9750510
    [Abstract] [Full Text] [Related]

  • 15. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
    Kylmälä T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I.
    Br J Cancer; 1995 May 01; 71(5):1061-4. PubMed ID: 7734300
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer.
    Westerhuis LW, Delaere KP.
    Eur J Clin Chem Clin Biochem; 1997 Feb 01; 35(2):89-94. PubMed ID: 9056749
    [Abstract] [Full Text] [Related]

  • 17. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
    Tanaka K, Shiraishi K, Sakamoto A, Jojima H, Masuchi K, Okubo Y, Tanaka M, Fuzimatsu Y, Fukahori S, Osabe S, Imamura Y, Honda J, Oizumi K.
    Rinsho Ketsueki; 1998 Apr 01; 39(4):273-80. PubMed ID: 9597894
    [Abstract] [Full Text] [Related]

  • 18. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M, Fukunaga M, Ohtawa T, Harada T.
    World J Surg; 1996 Sep 01; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Serum carboxy-terminal cross-linked telopeptide of type I collagen reflects bone metastasis in hepatocellular carcinoma.
    Ueno T, Hashimoto O, Sugawara H, Ogata R, Kusaba N, Torimura T, Sata M, Tanikawa K.
    Int J Oncol; 1998 Aug 01; 13(2):297-303. PubMed ID: 9664125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.